BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12877814)

  • 1. Analysis of TRAIL receptor expression using anti-TRAIL death receptor-5 monoclonal antibodies.
    Ma Y; Yang D; Chen Y
    Chin Med J (Engl); 2003 Jun; 116(6):947-50. PubMed ID: 12877814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells].
    Ma YF; Zhang J; Zhao YP; Yang DL; Chen YH
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):528-30. PubMed ID: 15555281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preparation and characterization of monoclonal antibody against DR5].
    Bai HL; Zhao YP; Liu GC; Ma YF
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):514-6, 520. PubMed ID: 16806020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adriamycin enhances anti-human DR5 monoclonal antibody (mDRA-6) induced HL-60 cells apoptosis].
    Li SL; Ma YF; Liu GC; Zhang J; Bai HL; Liu YJ; Lu F
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):461-4. PubMed ID: 17147249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis.
    Wang J; Lin Z; Qiao CX; Lv M; Yu M; Xiao H; Wang Q; Wang L; Feng J; Shen B; Ma Y; Li Y
    Cell Mol Immunol; 2008 Feb; 5(1):55-60. PubMed ID: 18318995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of monoclonal antibodies directed against trail or trail receptors.
    Vermot-Desroches C; Sergent E; Bonnin B; Wijdenes J
    Cell Immunol; 2005; 236(1-2):86-91. PubMed ID: 16157319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active.
    Miranda-Carús ME; Balsa A; Benito-Miguel M; De Ayala CP; Martín-Mola E
    Arthritis Rheum; 2004 Sep; 50(9):2786-93. PubMed ID: 15457446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.
    Mori E; Thomas M; Motoki K; Nakazawa K; Tahara T; Tomizuka K; Ishida I; Kataoka S
    Cell Death Differ; 2004 Feb; 11(2):203-7. PubMed ID: 14576771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytotoxic mechanism of anti-human death receptor 5 monoclonal antibody mDRA-6].
    Liu GC; Ma YF; Zhang J; Li SL; Lu F; Bai HL; Zhao YP
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Nov; 22(6):790-3. PubMed ID: 17077022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.